Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
azithromycin + erythromycin
- Development stage
- Unknown
- Lead developer
- PLIVA
- Modality
- Small Molecules
- Administration
- Oral, Intravenous, Topical, Ophthalmic
01
Overview
Azithromycin and erythromycin are macrolide antibiotics used to treat various bacterial infections. Both work by inhibiting bacterial protein synthesis, preventing bacteria from growing and multiplying. They are commonly used for respiratory infections (pneumonia, bronchitis), skin/skin-structure infections, and pharyngitis/tonsillitis. When used together, they may have additive effects on QT interval prolongation, potentially increasing the risk of ventricular arrhythmias.
- Brand names
- Zithromax + Erythrocin
02
Targets
23S rRNA (23S ribosomal RNA)CYP3A4 (Cytochrome P450 3A4)
Beyond the preview
Go deeper on azithromycin + erythromycin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on azithromycin + erythromycin.